**The role of sodium phosphate cotransporters in ectopic calcification**

**Sergio Gonzalo, Ricardo Villa-Bellosta**

Fundación Instituto de Investigación sanitaria, Fundación Jiménez Díaz, Madrid, Spain

**Abstract**

Phosphate plays a critical role in many vital cellular processes. Deviations from normal serum phosphate levels, including alterations in the extracellular phosphate/pyrophosphate ratio, can cause severe consequences, such as ectopic calcification. Cellular phosphate levels are tightly controlled by sodium phosphate cotransporters, underscoring their importance in cellular physiology. The role of sodium phosphate cotransporters in ectopic calcification requires further elucidation, taking into account their important role in the control of intracellular phosphate levels and the synthesis of ATP, the main source of extracellular pyrophosphate (a potent endogenous inhibitor of calcification). In this review, we discuss the roles of phosphate and pyrophosphate homeostasis in ectopic calcification, with a specific focus on phosphate transporters. We concentrate on the five known sodium-dependent phosphate transporters and review their localisation and regulation by external factors, and the effects observed in knockout studies and in naturally occurring mutations. (Endokrynol Pol 2019; 70 (6): 496–501)

**Key words:** phosphate; ectopic calcification; pyrophosphate; transporters; ATP

**Introduction**

**Phosphate**

Phosphate is required for many biological processes, including bioenergetics, metabolic regulation, cell signalling, cell proliferation, membrane integrity, and bone mineralisation [1, 2]. Organic phosphate that is ingested in foods is hydrolysed in the gastrointestinal tract, releasing inorganic phosphate. Aqueous phosphate exists in four forms, according to its triprotic equilibrium: 1 — trihydrogen phosphate (H$_3$PO$_4$), 2 — dihydrogen phosphate ion (H$_2$PO$_4$$^-$), 3) hydrogen phosphate ion (HPO$_4$$^{2-}$), and 4) phosphate ion (PO$_4$$^{3-}$). Phosphate is quite strong with respect to the first dissociation constant ($pK_{a1} = 2.1$), moderately weak with respect to the second ($pK_{a2} = 6.9$), and very weak with respect to the third ($pK_{a3} = 12.4$) [3].

The phosphate concentration in the plasma is determined by its intestinal intake, excretion through the faeces, release from bone and soft tissue, and renal excretion. The principal means by which mammals achieve phosphate homeostasis is through the control of its reabsorption along the renal proximal tubule (PT) [4].

Given its critical roles in vital cellular processes, it is not surprising that deviations from normal serum phosphate concentrations can cause severe clinical disorders. A phosphate deficiency typically results in muscle weakness, rhabdomyolysis, impaired leukocyte function, and abnormal bone mineralisation, leading to rickets or osteomalacia [5–7]. Elevated serum phosphate concentrations contribute to the pathogenesis of secondary hyperparathyroidism in patients with chronic renal failure [8, 9].

Although systematically underestimated in national surveys, phosphorus intake seemingly continues to increase as a result of the growing consumption of highly processed foods, in particular restaurant meals, fast foods, and convenience foods [10]. While a high dietary intake of phosphate increases its renal excretion, a low dietary phosphate intake increases its renal reabsorption.

Phosphate homeostasis is also influenced by many other factors. For example, the renal excretion of phosphate is increased by parathyroid hormone (PTH), 1,25-OH2-vitamin D3, fibroblast growth factor 23 (FGF23), dopamine, and glucocorticoids, and is also increased during acidosis or hypokalaemia [7, 11]. Moreover, the renal reabsorption of phosphate is increased by insulin, insulin-like growth factor 1 (IGF1), 1,25-OH2-vitamin D3, and thyroid hormone, as well as during alkalosis [12–15].
Phosphate and vascular calcification

Elevated serum phosphate is a known inducer of vascular calcification [16, 17], which is associated with increased mortality [18]. Elevated serum phosphate significantly increases the risk of cardiovascular disease, regardless of pre-existing diseases such as chronic kidney disease (CKD) [19]. Increased serum phosphate concentrations are associated with the thickening of the carotid intima-media and are a strong contributing factor to arteriosclerosis in haemodialysis patients [20]. Furthermore, even when within the normal range, higher serum phosphate levels are associated with a higher prevalence of vascular and valvular calcification in people with moderate CKD [21].

Vascular calcification occurs in distinct layers of the aortic wall and is associated with specific pathologies. Intimal calcification is observed in atherosclerotic lesions, whereas medial calcification, “Monckeberg’s medial sclerosis”, occurs in the medial layer of the aortic wall and is associated with the elastic lamina [22, 23].

Over the last few years, a relationship between phosphate transport and the initiation of vascular calcification has been increasingly investigated [24]. Nevertheless, our understanding of calcification pathogenesis is far from complete. Several mechanisms that govern the initiation and progression of vascular calcification have been suggested, including passive and active processes [17, 25]. At physiological calcium and phosphate serum concentrations, calcium phosphate deposition (CPD) is a passive process that does not require cellular activity [26–29]. For example, calcification occurs more slowly than in hyperphosphataemic conditions, but it is highly pronounced after 21 days in a model without cellular activity [27]. Nevertheless, given that living cells do not calcify under physiological conditions, vascular smooth muscle cells (VSMCs) must participate in the process by synthesising several CPD inhibitors [27].

On the other hand, the reduced capacity of VSMCs to synthesise and secrete calcification inhibitors is the active process that contributes to vascular calcification [16, 17, 28, 30, 31]. In the extracellular fluids there are a range of endogenous low and high molecular weight inhibitors, including: 1 — low molecular weight (such as pyrophosphate, the major direct inhibitor of CPD formation and growth); and 2 — small and medium-sized proteins (mainly calcium binding proteins such as osteopontin, fetuin-A, and matrix gla proteins) [16, 17]. Other inhibitors in the second group include proteins involved in phosphate homeostasis regulation, which could play a potential indirect role as inhibitors of calcification (including osteoprotegerin, klotho/FGF23, and vitamin K) [16, 17]. An inverse and direct relationship between vascular calcification and bone mass has been established in a rat model of CKD receiving a long-term high-phosphorus diet, highlighting the complex relationship between calcification and phosphate homeostasis. After 20 weeks, the rats receiving the high-phosphorus diet displayed a significant increase in serum phosphorus, PTH, and creatinine, as well as aortic calcification and a decrease in bone mass [32].

Phosphate transport and extracellular pyrophosphate metabolism

Extracellular pyrophosphate is a potent inhibitor of vascular calcification and directly inhibits calcium phosphate crystal formation and growth in vitro and in vivo [31, 33–35]. Extracellular pyrophosphate is produced by the hydrolysis of extracellular ATP by ectonucleotide pyrophosphate/phosphodiesterase 1 (eNPP1) to form pyrophosphate and AMP (Fig. 1) [36], which is hydrolysed to form adenosine and phosphate via ecto-5´ nucleotidase (NT5E, also called CD73). Moreover, pyrophosphate is degraded to phosphate by tissue non-specific alkaline phosphatase (TNAP). Both phosphate and adenosine can be recovered from the extracellular space for ATP generation by the mitochondria or through another metabolic pathway (Fig. 1). Phosphate is transported by sodium phosphate transporters that are described in the following section. Moreover, Ado is transported into cells by two known types of nucleoside transporters: concentrative nucleoside transporters (CNTs, SLC28) and equilibrative nucleoside transporters (ENTs, SLC29). Extracellular pyrophosphate metabolism begins with the transport of ATP to the extracellular milieu via an exocytotic mechanism and multiple types of membrane channels (Fig. 1). Studies show that loss-of-function mutations in eNPP1 [16], NT5E [37], and ENT1 [38] can also result in ectopic calcification. Therefore, the role of sodium-phosphate transporters (NPT) in the context of ectopic calcification is probably the main contributor to high intracellular phosphate and thus has implications for ATP synthesis [2].

Sodium phosphate cotransporters

Because of the negative electrochemical potential across the cell membrane, the movement of phosphate into the cell does not occur by simple diffusion. Sodium phosphate cotransporters enable cellular import, thereby controlling cellular Pi levels [13]. Three types of sodium-dependent phosphate transporter classes have been recognised in mammals: the NaPi-I (SLC17) family [39], the NaPi-II (SLC34) family [40], and the NaPi-III (SLC20) family [41]. Although the NaPi-I family
members were originally identified as phosphate transporters, the relatively low affinity of the NaPi-I family members for phosphate suggested that they more readily transport organic and inorganic anions, rather than phosphate. By contrast, the NaPi-II and NaPi-III family members transport phosphate with high affinity ($K_m \approx 0.1 \text{ mmol/L}$ or less) but display different affinities for $H_2PO_4^-$ and $HPO_4^{2-}$ ions [42–44].

In a very interesting review, Werner et al. [45] hypothesised that the original NaPi-IIb-related gene was duplicated early in vertebrate development and that the appearance of NaPi-IIa correlated with the development of the mammalian nephron. NaPi-II and NaPi-III exhibit conserved structural features that are consistent with a prokaryotic origin.

The physiological importance of sodium-phosphate cotransporters is underscored by the effects observed in knockout studies and in cases of naturally occurring mutations, as we review in the following sections and summarise in Table I.

**NaPi-II (SLC34 family)**

The NaPi-II (SLC34) family comprises three members: NaPi-IIa, NaPi-IIb, and NaPi-IIc [40]. They are high-affinity Pi transporters ($K_m \leq 100 \text{ mmol/L}$), exhibit a higher specificity for deprotonated phosphate ($HPO_4^{2-}$), and are specifically inhibited by phosphonoformic acid (PFA) [42].

All members of this family share a duplicated motif consisting of glutamine followed by a stretch of three-nine or serine residues [46]. The two isoforms, NaPi-IIa and NaPi-IIb, have distinct differences in three hydrophilic regions. These include the two termini and a segment within the glycosylated extracellular loop [45]. There are differences in the protein/protein interactions between NaPi-IIa and NaPi-IIc. Fewer PDZ proteins interact with NaPi-IIc compared with NaPi-IIa. NaPi-IIa interacts with NHERF1–4 (Na+/H+ exchanger regulatory factors 1–4), CALP (Golgi-associated PDZ and coiled-coil motif containing), and SHANK2E (SH3 multiple ankyrin repeat domains 2E), while NaPi-IIc only interacts with NHERF1 and NHERF3 [47, 48].

NaPi-IIa and NaPi-IIb are electrogenic and translocate one net positive charge per transport cycle [49]. By contrast, NaPi-IIc is electroneutral with no net charge translocation [50–52]. The members transport one divalent phosphate ion with an apparent affinity ($K_{0.5}^\Pi$) of 10–70 mmol/L, together with two (NaPi-IIc) or three Na ions (NaPi-IIa and NaPi-IIb) with an apparent affinity ($K_{0.5}^Na$) of 25–50 mmol/L [46].

**NaPi-IIa (SLC34A1)**

NaPi-IIa is expressed predominantly in the renal PTs and the osteoclast basolateral membrane. Under normal conditions, NaPi-IIa is the major transporter for phosphate reabsorption in the PT [43].

A recent study reported that the loss-of-function of NaPi-IIa (Table 1) results in nephrocalcinosis and possibly in kidney insufficiency [53]. Interestingly, NaPi-IIa has also been identified in the brain [54].
is hypothesised that NaPi-IIa in the brain is involved in phosphate sensing, which consequently suggests that the renal expression of NaPi-IIa may be centrally regulated [55].

Recently, it was demonstrated that NaPi-IIa is the only SLC34 member expressed during RANKL-induced osteoclast differentiation but is dispensable for osteoclast differentiation and bone resorption [56].

Within the first four hours after ingestion of a low-phosphate diet, brush border Na+/Pi cotransport increases due to a rise in NaPi-IIa levels [57, 58]. By contrast, NaPi-IIa abundance changes quickly in response to a high-phosphate intake (in less than one hour) throughout the PT. In this case, phosphate internalisation occurs in a microtubule-independent way, and molecules are targeted to the lysosome via endosomes [59, 60].

The global knockout of NaPi-IIa in mice results in skeletal abnormalities, hypophosphataemia with hyperphosphaturia, reduced PTH, and elevated 1,25-OH vitamin D3 levels with secondary hypercalcaemia and hypercalciuria. Idiopathic infantile hypercalcaemia [61].

Recently, it was shown that oestrogen specifically down-regulates NaPi-IIa, but not NaPi-IIc or Pit-2, in the kidney cortex through the activation of both oestrogen receptor isoforms (ERα and ERβ) in the rat kidney PT [62].

**NaPi-Ilb (SLC34A2)**

NaPi-Ilb expression has been detected in the small intestine, lungs, mammary glands, salivary gland, thyroid gland, testis, and liver [40].

Global NaPi-Ilb knockout is lethal [63], but NaPi-Ilb loss-of-function is associated with alveolar calcification in middle age [64, 65], and sometimes calcification in other organs, such as the testis (Tab. I) [64]. Intestine-specific ablation of NaPi-Ilb in mice results in viable pups with normal growth, but increased excretion of phosphate through the faeces and a complete absence of sodium-phosphate cotransport activity in BBM vesicles (BBMV) isolated from the ileum were observed. Notably, the absence of this transporter is fully compensated in adult females by a mechanism involving the bone-kidney axis [66].

It is likely that NaPi-Ilb mediates secondary active phosphate accumulation at the basolateral membrane and consequently reverses phosphate flux in mammalian secretory tissue [45].

**NaPi-IIc (SLC34A3)**

NaPi-IIc is expressed in the kidney and has been described a having growth-related functions [51, 52]. It is found in the BBM of the early PT (S1 segment) of the proximal tubules.
Phosphate transport and calcification

Sergio Gonzalo, Ricardo Villa-Bellosta

juxtamedullary nephrons. During phosphate depletion, NaPi-IIc is also detected in the early PT of superficial nephrons [51, 67, 68].

The global knockout of NaPi-Iic in mice results in hypercalcaemia, hypercalciuria, and increased 1,25-OH vitamin D3 levels (Tab. I) [69]. However, unlike in humans, the kidney-specific deletion of NaPi-Iic in mice does not disturb phosphate homeostasis, strongly suggesting an extrarenal role of NaPi-Iic in the intestine and/or bone [70] (Tab. I).

The role of NaPi-IIc in bone physiology is not clear. Although it regulates calcium metabolism [69], it was recently described to have no role in osteoclast differentiation and function [56].

**NaPi-III (SLC20 family)**

Although NaPi-IIa and NaPi-IIc are the principal mediators of renal phosphate reabsorption, significant phosphate reabsorption remains in both knockout animals. This observation suggested the existence of other phosphate transporters: the SLC20 family. This family, also called NaPi-III, comprises two members: Pit-1 and Pit-2 [41]. These were originally identified as cell surface receptors for gibbon ape leukaemia virus (Glvr-1) and rat amphotropic leukaemia virus (Ram-1), respectively [71, 72].

Pit-1 and Pit-2 mediate the movement of phosphate ions across the cell membrane [73, 74] and are ubiquitously expressed. VSMCs express both phosphate transporters, but Pit-1 [24, 75] is more abundant than Pit-2 [76].

Pit-1 and Pit-2 are electrogenic, with a coupling stoichiometry of > 1 Na⁺ ions per Pi ion cotransported [41], but unlike NaPi-IIa and NaPi-IIc, they display a preference for monovalent phosphate and a reduced sensitivity to pH and the phosphate transport inhibitor PFA [73, 77].

The current model predicts a 12 transmembrane domains structure, but in contrast to the SLC34 family proteins, the N- and C-termini are both extracellular [78, 79].

A recent study proposes that Pit-1 and Pit-2 are the main transporters responsible for sodium-driven phosphate uptake in osteoclasts [56]. In fact, their involvement in vascular calcification [76, 80, 81] and bone mineralisation [82] suggests a key role in vascular and skeletal pathologies. VSMCs have both Na-dependent and Na-independent phosphate transport components with a similar kinetic behaviour, but only Na-coupled saturable uptake can be attributed to the expression of both Pit-1 and Pit-2 [73, 76]. Recently, Pit-1 and Pit-2 gene expression was shown to be upregulated in Npt2a-null mice during metabolic acidosis, suggesting a possible compensatory role for SLC20 proteins [83].

The expression level and thereby the transport activity of the NaPi-III protein family are regulated by the extracellular phosphate level [84–87]. For instance, phosphate uptake and Pit-1 and Pit-2 mRNA levels were higher in 208F rat fibroblasts grown in a Pi-free medium. Similarly, in human embryonic kidney cells, phosphate deprivation stimulated Pit-1-mediated phosphate uptake [88], and an increase in Pit-2 mRNA and protein levels was reported for two osteosarcoma cell lines [84]. We showed that rats receiving a long-term high-phosphate (1.2%) diet exhibit a significant decrease in Pit-2 protein expression in the kidney compared with that of rats maintained on a long-term low-phosphate (0.1%) diet [89].

**Pit-1 (SLC20A1)**

Pit-1 mRNA expression is highest in osteoblasts, VSMCs, and bone marrow [73, 76, 82]. Pit-1 plays a critical role in cartilage calcification and the regulation of apoptosis and cell proliferation [90–93].

Various transport-independent functions of Pit-1 have been described that may help explain the role of Pit-1 in VC: the transporter is involved not only in the modulation of cell proliferation [91] but also in the regulation of TNF-α-induced apoptosis and mitogen-activated protein kinase (MAPK) activation [91], which are related to calcification pathogenesis. The deletion of Pit-1 in the mouse suggests that Pit-1 plays an essential function in liver development (Tab. I) [94]. The targeted deletion of Pit-1 in VSMCs in the mouse did not induce aortic calcification due to compensatory regulation by Pit-2 [95]. Moreover, loss of function in Pit-1 results in cartilage calcification (Tab. I) [92]. In contrast to Pit-2, a global Pit-1 knockout is embryonically lethal in mice (Tab. I) [94].

**Pit-2 (SLC20A2)**

The expression of Pit-2 is highest in VSMCs, liver, heart, and brain, and it is also localised in the BBM of the PT epithelia [41, 73, 89]. Recently, it was reported that Pit-2 is required for normal placental function and that its deficiency results in foetal growth restriction and placental calcification [96].

Pit-2 mutations have been identified in patients with familial idiopathic basal ganglia calcification (FIBCG) [97], suggesting that the functional loss of phosphate transport can produce a decrease in the synthesis of CPD inhibitors and a local phosphate accumulation in the extracellular matrix, both contributing to the consequent increase of CPD (Tab. I). No abnormalities in serum electrolytes or calciotropic hormones and no obvious bone phenotype have been described in FIBCG patients. Pit-2 KO mice recapitulate the human disease in that they exhibit basal ganglia calcification [98].
Previous studies reported that PiT-2 is significantly down-regulated in the BBM in rats switched from a long-term low-Pi to a high-Pi diet after only 24 hours [89]. For the reverse dietary regime, PiT-2 displayed a slower adaptive trend. These findings suggest that PiT-2, until now considered to be a ubiquitously expressed phosphate housekeeping transporter, is a novel mediator of phosphate reabsorption in the PT during acute phosphate deprivation and acidosis conditions [43], and that it displays a different adaptive time course than NaPi-IIa and NaPi-IIc [89].

The influence of pH on NaPi cotransporters

One of the most important factors that affects NaPi transporters is the pH. NaPi-IIa and NaPi-IIc activity is highest at alkaline pH levels, whereas Pit-1 and Pit-2 are maximally activated at low pH levels [43]. In addition, while chronic adaptation to a low-phosphate diet increases the expression of NaPi-IIa, NaPi-IIc, and Pit-2 protein and increases the phosphate transport V_{\text{max}} in BBMVs at pH 7.5, the increase in transport is minimised when uptake takes place at pH 6.0 (i.e. when Pit-2 is maximally activated but NaPi-IIa and NaPi-IIc are inhibited by 90%). In contrast to the renal type II isofrom, type IIb-associated sodium-phosphate cotransport was less dependent on the pH and was slightly higher at more acidic pH values [43,99]. These biochemical differences suggest that each transporter has a specific role in the PT to avoid physiological redundancy.

Conclusions and future perspectives

The maintenance of appropriate phosphate homeostasis is vital to avoid negative health consequences, such as calcification in soft tissues. Sodium phosphate cotransporters are key players in these processes, and their importance has been underscored in different studies demonstrating the effects of the alteration in their expression and loss of function (Tab. I).

Understanding sodium phosphate cotransporter function and regulation is very useful for improving the treatment and prevention of ectopic calcification, because they play critical roles in maintaining phosphate homeostasis and in the intracellular synthesis of ATP. Moreover, we propose that not only phosphate homeostasis but also pyrophosphate homeostasis must be taken into account in the design of therapeutic strategies for ectopic calcification [25].

Funding

R.V.B. is supported by grants from the Spanish Ministerio de Economía y Competitividad (SAF-2014-60699-JIN) and Progeria Research Foundation (PRF2016-68).

Disclosures

No conflicts of interest, financial or otherwise, are declared by the authors.

References


